Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH Apr 1, 2019
Poxel to Report Full Year 2018 Financial Results and Host Conference Call on March 21, 2019 Mar 11, 2019
Poxel Announces Initiation of Part 2 of Phase 1a Study for PXL065, which is being Developed for the Treatment of NASH Nov 26, 2018
Poxel Presents Promising Data for PXL770 and PXL065 for the Treatment of NASH at the American Association for the Study of Liver Diseases Meeting Nov 12, 2018
